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The Role of Radiopharmaceuticals MIBG and (V) DMSA in the
Diagnosis of Medullary Thyroid Carcinoma
Uberta Verga,* Fabrizio Muratori,* Gianleone Di Sacco,* Francesco Banfi,*
and Alfonso Libroia*

The diagnostic value of'""-"I meta-iodo-benzylguanidine (MIBG) and ''''"'Tc (V) dimercaptosuccinic
acid (DMSA) was investigated in 12 patients with proven medullary thyroid carcinoma (MTC).
Scintigraphic imaging with DMSA was negalive in nine of 12 patients. Scintigraphy with MIBG was
positive in only one case. In proven primary or recurrent disease, DMSA sensitivity was 50% and
MIBG .sensitivity was 25%. Such sensitivities become much lower in subjects wilh high calcitonin (CT)
levels who have had negative surgical explorations: DMSA 17% and MIBG 0%. DMSA delected tumor
in 25% of the patients and MIBG in only 8%. The positivity of these scintigraphies appears to be
unrelated to carcinoembryonic antigen and CT plasma levels. Such data suggest that .scintigraphies
wilh MIBG and DMSA are only modestly useful in the diagnosis of MTC. (Henry Ford Hosp Med J
1989:37:175-7)

n the follow-up of patients treated by total thyroidectomy for
medullary thyroid carcinoma (MTC), the presence of high
baseline calcitonin (CT) levels and/or remarkably increased CT
tevels after calcium or pentagastrin infusion represent evidence
of recunent disease. The tumor may metastasize locally or to
bones and soft tissue (1); such metastases are difficult to detect
with the commonly available techniques. To localize tumor recunence, various imaging methods have been used, including
ultrasound and axial computed tomography. Several reports
have suggested a potential diagnostic and therapeutic role of ' " I
meta-iodo-benzylguanidine (MIBG) in MTC (2). The radioiodinated MIBG uptake in MTC is not surprising because C-celts
originate from the ectodermal neural crest as do many ofthe
other neoplasms imaged with this agent. The most encouraging
results seem to be offered by ""Tc (V) dimercaptosuccinic acid
(DMSA) which accumulates in the tumor and metastatic sites.
Nevertheless, several authors report conflicfing data (3,4). To
gain further knowledge regarding the use of MIBG and DMSA,
we investigated a group of 12 patients with histologically proven
MTC.

I

thyroidectomy and showed high CT seram levets only after calcium and pentagastrin stimulation. Nine of the 12 subjects atso
showed elevated carcinoembryonic antigen (CEA) levels.
CT and CEA measurement
The quantitative determination of CT in serum was measured
using a radioimmunologic method (RIA-mat Calcitonin I I ,
Byk-Santec Diagnostica Dietzenbach, RFA). CEA values
were defined using a monoclonal radioimmunologic method
(Ammerwell CEA Assay monoclonal Amersham). The nonnal
values were below 150 pg/mL for seram CT levels and below 5
ng/mL for plasma CEA levels.
MIBG
MIBG scintigraphies were performed after an intravenous
injection of 90 MBq of " ' I MIBG or 185 MBq of '^^ MIBG.
Imaging with " ' I MIBG was performed at 24 and 48 hours and
with '-T MIBG at 4 and 24 hours after. All patients received
blocking doses of Lugol's iodine solution orally (60 mg potassium iodide twice daily beginning two days before the start of
the study and continuing throughout its duration).

Methods
Patients
Twelve patients, four females and eight males aged 11 to 67,
were studied. Five patients belonged to two muttiple endocrine
neoplasia type 2A (MEN 2A) families and seven had sporadic
MTC. Of the 11 patients with elevated basal plasma CT levels,
ten had previously undergone total thyroidectomy and
lymphadenectomy and one was studied both before and after
partial ablation of the neoplastic masses in the neck. The twelfth
patient, a member of a MEN 2A family, had not yet had total
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DMSA
Two commerciat kits of Tc (V) DMSA were obtained using
controlled atkalination of the Tc(III) DMSA mixture commonly
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Table
Comparison Between (V) DMSA, MIBG, and Other Investigations
I'.Uiclll

1
2
3
4
5
6
7
8
9
in
II
12

Age
(years)
63
29
24
.^11

12
4(.
29

<,s
65
42
19
;ii

Diagnosis
S P
M/R
S/R
SK
MlP
S/R
M/R
S/R
S/R
S/R
M/R
M/R

Total
Thvroideclomv

34-

•

-

3-

3-

•

333-

CEA'"

Basal

9.9
>60
>60
>60
2.2
4.0
17.2
>60
7.2
11.0
>60
0.9

•IOOO
475
> 1(K)0
> 1(X)()
51
409
200
>I000
223
274
410
258

'' For norniul values sec text.
' Mainlained positivity after partial ablation of tumor mass.
tAt'ter scintigraphy investigalinn.
S - sporadic. M ^ MEN 2A. P = primary lutDor. R = recurrent disease.

used for kidney scanning. DMSA scintigraphies were performed two to three hours after an intravenous administration of
370 to 444 MBq of "'"Tc (V) DMSA. Quality control of ""Tc
(V) DMSA at the time of preparation ensured that the material
administered was alkaline (pH 8 to 8.5).
These scintigraphies were performed using a large field of
view gamma camera with high resolution collimator interfaced
to a data processor The two types of scintigraphies were performed within a one-month period.

Results
Nine of 12 scintigraphic imagings with DMSA gave negative
responses, while scintigraphy with MIBG was positive in only
one case (Table). Both DMSA and MIBG gave positive responses only in the patient with the priinary tumor. This patient
had a large mass in the neck area which was positive to scintigraphy with both tracers before and after partial ablation. The two
subjects who were positive with DMSA but not with MIBG had
recurrent disease, one with histologically positive lateral cervical lymph nodes and one with uptake in the tenth left rib and
skull. Computed axial tomography confirmed the presence ofa
rib lesion. Two of the nine subjects with negative responses to
DMSA and MIBG had histologically positive lateral cervical
masses; one was the only patient who showed an accumulation
in the renal areas. A third subject had two intrathyroid neoplastic foci. The positivity of these scintigraphies did not conelate with CEA and CT plasma levels.

Discussion
The diagnosis of MTC recurrence is based on the assay of
plasma CT and CEA levels because high CT levels are known to
be related to residual tumor or recunences (5) and elevated
plasma CEA levels often indicate more aggressive tumors (6).
However, traditional imaging techniques do not have high sen-
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sitivity in localizing residual tumor Scanning with """Tc (V)
DMSA and " ' I MIBG has been proposed. MIBG, an analog of
the adrenergic blocking agent, has been used for the localization
of pheochromocytoma and may accumulate in MTC as well (7).
The mechanism of (V) DMSA concentration in neoplastic sites
is not clear The nonspecific accumulation of this radiotracer in
the neoplastic sites may be related to local abnormalities of
phosphorus and calcium metabolism (8). Most reports show a
much lower diagnostic efficacy for MIBG in comparison with
DMSA (9). However, MIBG has a potential therapeutic role in
MTC (10).
Guerra et al (11), reporting the data available in literature,
showed that DMSA sensitivity is about 80% for primary tumors
and 68% for recurrent diseases. Although these data seem encouraging, the investigations have mainly involved subjects
with tumoral lesions already evident. In the 12 subjects of our
study, one true positive was observed with MIBG, three true
positives with DMSA, and no false-posifives. Other investigations identified tumoral lesions in six of the 12 patients. By considering only those patients who presented with primary tumors
or recunent disease already proven at the time of scintigraphic
investigation (pafients 1 to 4), DMSA sensitivity is 50% (or 66%
not considering patient 2 with tracer kidney uptake) and MIBG
sensitivity is 25%. Such sensitivities are much lower when considering those subjects with high CT levels and other negative
invesfigation (all 12 subjects); DMSA 25% and MIBG 8%. In
subjects with high CT levels and negative explorations (patients
5 to 12). DMSA sensitivity is about 17% and MIBG 0%.
Our data show that DMSA and MIBG scintigraphies can
efficaciously identify tumor lesions that are already evident and
have a much lower sensitivity when such lesions are not obvious. These scintigraphic approaches are of only modest utility
in the postoperative follow-up of MTC patients. However,
MIBG is useful in the diagnosis of pheochromocytoma (12) and
has a potential therapeutic role in MTC. A radioiodinated analog of sandostatin ('-T-Iabeled tyr-3-octreoite) has been
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recently investigated to label somatostatin receptors in endocrine-related tumors in vivo and to localize tumors that present
membrane-bound somatostarin receptors (13).
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